Balloon Pulmonary Angioplasty in Patients with Chronic
Thromboembolic Pulmonary Hypertension: Impact on Clinical and
Hemodynamic Parameters, Quality of Life and Risk Profile

J 2020

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile

JANSA, Pavel, Samuel HELLER, Michal SVOBODA, Michal PAD'OUR, David AMBROZ et. al.

Základní údaje

Originální název

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile

Autoři

JANSA, Pavel (203 Česká republika, garant), Samuel HELLER (203 Česká republika), Michal SVOBODA (203 Česká republika, domácí), Michal PAD'OUR (203 Česká republika), David AMBROZ (203 Česká republika), Vladimir DYTRYCH (203 Česká republika), Michal SIRANEC (203 Česká republika), Tomas KOVARNIK (203 Česká republika), Marián FELŠŐCI (703 Slovensko, domácí), Martin HUTYRA, Ales LINHART (203 Česká republika), Jaroslav LINDNER a Michael ASCHERMANN (203 Česká republika)

Vydání

Journal of Clinical Medicine, BASEL, MDPI, 2020, 2077-0383

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.241

Kód RIV

RIV/00216224:14110/20:00117462

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/jcm9113608

UT WoS

000593224900001

Klíčová slova anglicky

chronic thromboembolic pulmonary hypertension; balloon pulmonary angioplasty; efficacy; safety; quality of life; risk profile; survival

Štítky

14110211, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 12. 2020 08:43, Mgr. Tereza Miškechová

Anotace

V originále

Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (-18%, p < 0.001), pulmonary vascular resistance (-32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.

Citovat

JANSA, Pavel, Samuel HELLER, Michal SVOBODA, Michal PAD'OUR, David AMBROZ, Vladimir DYTRYCH, Michal SIRANEC, Tomas KOVARNIK, Marián FELŠŐCI, Martin HUTYRA, Ales LINHART, Jaroslav LINDNER a Michael ASCHERMANN. Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile. Journal of Clinical Medicine. BASEL: MDPI, 2020, roč. 9, č. 11, s. 1-15. ISSN 2077-0383. Dostupné z: https://dx.doi.org/10.3390/jcm9113608.

@article{1713438,
   author = {Jansa, Pavel and Heller, Samuel and Svoboda, Michal and Pad'our, Michal and Ambroz, David and Dytrych, Vladimir and Siranec, Michal and Kovarnik, Tomas and Felšőci, Marián and Hutyra, Martin and Linhart, Ales and Lindner, Jaroslav and Aschermann, Michael},
   article_location = {BASEL},
   article_number = {11},
   doi = {http://dx.doi.org/10.3390/jcm9113608},
   keywords = {chronic thromboembolic pulmonary hypertension; balloon pulmonary angioplasty; efficacy; safety; quality of life; risk profile; survival},
   language = {eng},
   issn = {2077-0383},
   journal = {Journal of Clinical Medicine},
   title = {Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile},
   url = {https://www.mdpi.com/2077-0383/9/11/3608},
   volume = {9},
   year = {2020}
}

TY  - JOUR
ID  - 1713438
AU  - Jansa, Pavel - Heller, Samuel - Svoboda, Michal - Pad'our, Michal - Ambroz, David - Dytrych, Vladimir - Siranec, Michal - Kovarnik, Tomas - Felšőci, Marián - Hutyra, Martin - Linhart, Ales - Lindner, Jaroslav - Aschermann, Michael
PY  - 2020
TI  - Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile
JF  - Journal of Clinical Medicine
VL  - 9
IS  - 11
SP  - 1-15
EP  - 1-15
PB  - MDPI
SN  - 20770383
KW  - chronic thromboembolic pulmonary hypertension
KW  - balloon pulmonary angioplasty
KW  - efficacy
KW  - safety
KW  - quality of life
KW  - risk profile
KW  - survival
UR  - https://www.mdpi.com/2077-0383/9/11/3608
L2  - https://www.mdpi.com/2077-0383/9/11/3608
N2  - Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (-18%, p < 0.001), pulmonary vascular resistance (-32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.
ER  -

JANSA, Pavel, Samuel HELLER, Michal SVOBODA, Michal PAD'OUR, David AMBROZ, Vladimir DYTRYCH, Michal SIRANEC, Tomas KOVARNIK, Marián FELŠ$\backslash$H OCI, Martin HUTYRA, Ales LINHART, Jaroslav LINDNER a Michael ASCHERMANN. Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile. \textit{Journal of Clinical Medicine}. BASEL: MDPI, 2020, roč.~9, č.~11, s.~1-15. ISSN~2077-0383. Dostupné z: https://dx.doi.org/10.3390/jcm9113608.

Podrobný výpis o publikaci